
Gilead to Acquire Ouro Medicines to Fast-Track T Cell Engager for Autoimmune Diseases
Gilead Sciences agreed to buy Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestones to add OM336, a BCMAxCD3 T cell engager, to its inflammation portfolio. OM336 has shown rapid B cell depletion with a favorable safety profile in Phase 1/2 data and has FDA Fast Track and Orphan Drug designations, with registrational studies expected in 2027. Gilead is also in advanced talks for a collaboration with Galapagos, under which Galapagos would fund half of upfront and milestone payments, absorb Ouro’s operating assets, and receive 20-23% royalties on net sales while Gilead retains worldwide commercialization rights. The combined effort aims to accelerate immune-reset therapies for autoimmune diseases and potentially deliver durable, drug-free remission through BCMA-targeted T cell engagers.








